News & Updates
Filter by Specialty:
Refractory Crohn’s disease responds well to risankizumab
In the treatment of patients with luminal Crohn’s disease and multiple prior drug failures, risankizumab induces clinical response in about three out of four patients and steroid-free clinical remission in about half, according to a study.
Refractory Crohn’s disease responds well to risankizumab
09 Jan 2023
Oseltamivir as good as peramivir in influenza B but yields better outcomes in influenza A
Oseltamivir appears to have similar efficacy as peramivir in the treatment of young children with severe influenza B, a study has found. However, oseltamivir treatment leads to better recovery and shorter hospitalization in children with severe influenza A.
Oseltamivir as good as peramivir in influenza B but yields better outcomes in influenza A
08 Jan 2023
Capivasertib + fulvestrant boosts PFS in AI-resistant HR+/HER2– advanced breast cancer
The AKT inhibitor capivasertib, when added to fulvestrant, doubled progression-free survival (PFS) in patients with aromatase inhibitor (AI)-resistant hormone receptor-positive (HR+)/HER2*-negative (HER2–) advanced breast cancer (ABC), results of the phase III CAPItello-291 trial showed.
Capivasertib + fulvestrant boosts PFS in AI-resistant HR+/HER2– advanced breast cancer
08 Jan 2023
Higher plasma omega-3 PUFA levels tied to better large arterial elasticity
Increased plasma levels of total and individual omega-3 (n-3) polyunsaturated fatty acids (PUFAs) appear to be associated with higher large artery elasticity (LAE) among persons free of baseline cardiovascular disease (CVD), results of a multi-ethnic study have shown.
Higher plasma omega-3 PUFA levels tied to better large arterial elasticity
08 Jan 2023
Smartphone app supports self-management strategies for bipolar disorder
A smartphone-based self-management intervention may reduce relapse risk and manic symptom severity for patients with bipolar disorder in asymptomatic recovery, a randomized clinical trial has shown.
Smartphone app supports self-management strategies for bipolar disorder
08 Jan 2023
Adagrasib shows antitumour activity in KRAS G12C-mutant colorectal cancer
Adagrasib appears to have some effect against metastatic, KRAS G12C-mutated colorectal cancer when used in treatment-experienced patients either as oral monotherapy or in combination with cetuximab, according to the results of a phase I-II, open-label study.